Stonegate Initiates Coverage on Sirona Biochem Corp (TSX-V:SBM)
Paid press release content from Reportable. The StreetInsider.com news staff was not involved in its creation.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailDALLAS, TX -- October 17th, 2024 -- Sirona Biochem Crop (TSX-V:SBM): Stonegate Capital Partners initiates their coverage on Sirona Biochem Corp (TSX-V:SBM).
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- GlycoProteMim™ is a potential standout in the premium skincare market
- Sirona is targeting profitability by 2025, with expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim™ set to drive growth.
- Sirona’s partnerships place it in a strong position to capture market share in the growing global skincare industry.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
[email protected]
Source: Stonegate, Inc.
Distributed by: Reportable, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rabbi Steve Karro Establishes Arts Scholarship to Assist Undergraduate Students Nationwide
- Southern Company's experienced storm response teams, advanced storm intelligence technologies drive power restoration following Hurricane Isaias
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic
Create E-mail Alert Related Categories
Press Releases, ReportableSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
